ASCO

AnnualMeeting2016

Phase II POPLAR trial evaluating Atezolizumab in advanced NSCLC

519 0 Acute Lymphoblastic Leukemia Free

Phase II POPLAR trial evaluating Atezolizumab in advanced NSCLC
Want to watch this again later?
Sign in to add this video to a playlist. Login

Trending

Smoking does not predispose higher response rate to Atezolizumab from IMvigor 210

Smoking does not predispose higher response rate to Atezolizumab from IMvigor 210

Autoimmune can be delayed in immunotherapy Fadi Braiteh, MD

Autoimmune can be delayed in immunotherapy Fadi Braiteh, MD

Mutation load and gene profiles appear to have a significant impact on response rates and survival

Mutation load and gene profiles appear to have a significant impact on response rates and survival

PD-L1 expression in tumor and immune cells in the microenvironment from the POPLAR trial

PD-L1 expression in tumor and immune cells in the microenvironment from the POPLAR trial

Deficient mismatch repair in urothelial cancer

Deficient mismatch repair in urothelial cancer

Best way to test newly diagnosed NSCLC in the community setting

Best way to test newly diagnosed NSCLC in the community setting

Atezolizumab differences in Squamous Cell Carcinomas versus the Non-Squamous Cancers #Annual Meeting16

Atezolizumab differences in Squamous Cell Carcinomas versus the Non-Squamous Cancers #Annual Meeting16

Percentage of patient with urothelial cancer that are cisplatin ineligible

Percentage of patient with urothelial cancer that are cisplatin ineligible

Are safety and adverse event profile appears similar between early trials in both Anti PD-1 and Anti PD-L1

Are safety and adverse event profile appears similar between early trials in both Anti PD-1 and Anti PD-L1

Predictive and Prognostic biomarkers for Brain Metastasis

Predictive and Prognostic biomarkers for Brain Metastasis

ANG1005 shows promise for patients with leptomenigeal disease

ANG1005 shows promise for patients with leptomenigeal disease

ANG1005 side effect profile

ANG1005 side effect profile

My videos
Predictive and Prognostic biomarkers for Brain Metastasis
00:00:58

Predictive and Prognostic biomarkers for Brain Metastasis
750 Views
3 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
ANG1005 side effect profile
00:00:37

ANG1005 side effect profile
598 Views
3 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
ANG1005 shows promise in Brain Cancer
00:01:10

ANG1005 shows promise in Brain Cancer
619 Views
3 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Blood Brain Barrier and TKI in Brain Cancer treatment
00:01:07

Blood Brain Barrier and TKI in Brain Cancer treatment
713 Views
3 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Treating Brain Metastasis is being redefined due to genomic profiling
00:01:29

Treating Brain Metastasis is being redefined due to genomic profiling
930 Views
3 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
PD-L1 and Triple Negative Breast Cancer
00:00:42

PD-L1 and Triple Negative Breast Cancer
633 Views
3 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Current and future Immunotherapy outlook in breast cancer from Annual Meeting 2016
00:01:57

Current and future Immunotherapy outlook in breast cancer from Annual Meeting 2016
871 Views
3 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
PALOMA trials summary and Palbociclib in ER-positive breast cancer
00:05:15

PALOMA trials summary and Palbociclib in ER-positive breast cancer
641 Views
3 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Important to biopsy a growing lesion in lung cancer
00:00:36

Important to biopsy a growing lesion in lung cancer
341 Views
4 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Some patients saw dramatic improvement in IMvigor 210 trial
00:00:43

Some patients saw dramatic improvement in IMvigor 210 trial
407 Views
4 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Are safety and adverse event profile appears similar between early trials in both Anti PD-1 and Anti PD-L1
00:00:49

Are safety and adverse event profile appears similar between early trials in both Anti PD-1 and Anti PD-L1
224 Views
4 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Annual Meeting 2016 update on Small Cell Lung Cancer agents
00:00:59

Annual Meeting 2016 update on Small Cell Lung Cancer agents
456 Views
4 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Previous cytotoxin patients thought they were on placebo during atezolizumab trial due to low toxicity side effects
00:01:34

Previous cytotoxin patients thought they were on placebo during atezolizumab trial due to low toxicity side effects
215 Views
4 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
IMvigor210 response rate durability of response and stable disease
00:01:24

IMvigor210 response rate durability of response and stable disease
266 Views
4 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
POPLAR trial endpoints median duration of response overall survival and the impact of PD-L1 expression
00:01:04

POPLAR trial endpoints median duration of response overall survival and the impact of PD-L1 expression
261 Views
4 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Second line treatment of NSCLC patients before immuno-oncology
00:02:05

Second line treatment of NSCLC patients before immuno-oncology
589 Views
4 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
All comers are eligible in second line urothelial cancer with Atezolizumab
00:01:14

All comers are eligible in second line urothelial cancer with Atezolizumab
467 Views
4 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Annual Meeting 2016 update on MET in NSCLC
00:01:10

Annual Meeting 2016 update on MET in NSCLC
444 Views
4 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Some patients saw dramatic improvement in IMvigor 210 trial
00:00:43

Some patients saw dramatic improvement in IMvigor 210 trial
431 Views
4 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
POPLAR trial success leads to larger OAK study
00:00:28

POPLAR trial success leads to larger OAK study
609 Views
4 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Autoimmune can be delayed in immunotherapy
00:00:31

Autoimmune can be delayed in immunotherapy
533 Views
4 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Phase II POPLAR trial evaluating Atezolizumab in advanced NSCLC
00:00:30

Phase II POPLAR trial evaluating Atezolizumab in advanced NSCLC
519 Views
4 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Nivolumab and Pembrolizumab experience in the second line therapy of your NSCLC patients
00:03:52

Nivolumab and Pembrolizumab experience in the second line therapy of your NSCLC patients
873 Views
4 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Phase III NEMO trial and the novel MEK inhibitor Binimetinib
00:01:11

Phase III NEMO trial and the novel MEK inhibitor Binimetinib
911 Views
4 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login